Pharmacokinetic- pharmacodynamic analysis of the role of CYP2C19 genotypes in short-term rabeprazole-based triple therapy against Helicobacter pylori

British Journal of Clinical Pharmacology

Volumn 67, Issue 5, 2009, Pages 503-510

  Yang, Jyh Chin ^a   Yang, Yu Fan ^b   Uang, Yow Shieng ^c   Lin, Chun Jung ^b   Wang, Teh Hong ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

CYP2C19 polymorphism; Helicobacter pylori; Population PK PD; Rabeprazole

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; CYTOCHROME P450 2C19; DRUG METABOLIZING ENZYME; GASTRIN; RABEPRAZOLE;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG RESISTANCE; ERADICATION THERAPY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HOMOZYGOSITY; HORMONE RESPONSE; HUMAN; MALE; PHARMACODYNAMICS; PHARMACOGENETICS; POPULATION RESEARCH; PRIORITY JOURNAL; SHORT COURSE THERAPY; STOMACH ULCER; TREATMENT DURATION;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADOLESCENT; ADULT; AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ARYL HYDROCARBON HYDROXYLASES; CLARITHROMYCIN; FEMALE; GENOTYPE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 65349128783     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2009.03393.x     Document Type: Article

References (38)

1. Moss SF, Sood S. Helicobacter pylori. Curr Opin Infect Dis 2003 16 : 445 51.
2. Howden CW, Hunt RH. Guidelines for the management of Helicobacter pylori infection. Am J Gastroenterol 1998 93 : 2330 8.
3. Chey WD, Wong BC. Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007 102 : 1808 25.
4. Calvet X, Gene E, Lopez T, Gisbert JP. What is the optimal length of proton pump inhibitor-based triple therapies for H. pylori? A cost-effectiveness analysis. Aliment Pharmacol Ther 2001 15 : 1067 76.
5. Gisbert JP, Khorrami S, Calvet X, Pajares JM. Systematic review: rabeprazole-based therapies in Helicobacter pylori eradication. Aliment Pharmacol Ther 2003 17 : 751 64.
6. Vakil N, Schwartz HJ, Lanza FL, Nardi L, Hahne W, Barth J. A prospective, controlled, randomized trial of 3-, 7-, and 10-day rabeprazole-based triple therapy for H. pylori eradication in the USA. Gastroenterology 2002 122 (Suppl. 4 A65.
7. Luth S, Teyssen S, Kolbel CB, Singer MV. 4-day triple therapy with rabeprazole, amoxicillin and clarithromycin in the eradication of Helicobacter pylori in patients with peptic ulcer disease - a pilot study. Z Gastroenterol 2001 39 : 279 85.
8. Sachs G, Shin JM, Vagin O, Lambrecht N, Yakubov I, Munson K. The gastric H,K-ATPase as a drug target: past, present and future. J Clin Gastroenterol 2007 41 : S226 42.
9. Klotz U, Schwab M, Treiber G. CYP2C19 polymorphism and proton pump inhibitors. Basic Clin Pharmacol Toxicol 2004 95 : 2 8.
10. Goldstein JA, Ishizaki T, Chiba K, de Morais SM, Bell D, Krahn PM, Evans DA. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997 7 : 59 64.
11. Besancon M, Simon A, Sachs G, Shin JM. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thio reagents. J Biol Chem 1997 272 : 22438 46.
12. Tsutsui N, Taneike I, Ohara T, Goshi S, Kojio S, Iwakura N, Matsumaru H, Wakisaka-Saito N, Zhang HM, Yamamoto T. A novel action of the proton pump inhibitor rabeprazole and its thioether derivative against the mobility of Helicobacter pylori. Antimicrob Agents Chemother 2000 44 : 3069 73.
13. Tsuchiya M, Imamura L, Park JB, Kobashi K. Helicobacter pylori urease inhibition by rabeprazole, a proton pump inhibitor. Biol Pharm Bull 1995 18 : 1053 6.
14. Williams MP, Pounder RE. Review article: the pharmacology of rabeprazole. Aliment Pharmacol Ther 1999 13 (Suppl. 3 3 10.
15. Inaba T, Mizuno M, Kawai K, Yokota K, Oguma K, Miyoshi M, Take S, Okada H, Tsuji T. Randomized open trial for comparison of proton pump inhibitors in triple therapy for Helicobacter pylori infection in relation to CYP2C19 genotype. J Gastroenterol Hepatol 2002 17 : 748 53.
16. Horai Y, Kimura M, Furuie H, Matsuquma K, Irie S, Koga Y, Nagahama T, Murakami M, Matsui T, Yao T, Urae A, Ishizaki T. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes. Aliment Pharmacol Ther 2001 15 : 793 803.
17. Lin CJ, Yang JC, Uang YS, Chern HD, Wang TH. Time-dependent amplified pharmacokinetic and pharmacodynamic responses of rabeprazole in cytochrome P450 2C19 poor metabolizers. Pharmacotherapy 2003 23 : 711 9.
18. Sugimoto M, Furuta T, Shirai N, Kodaira C, Nishino M, Yamade M, Ikuma M, Watanabe H, Ohashi K, Hishida A, Ishizaki T. Treatment strategy to eradicate Helicobacter pylori infection: impact of pharmacogenomics-based acid inhibition regimen and alternative antibiotics. Expert Opin Pharmacother 2007 8 : 2701 17.
19. Yang JC, Yang KC, Hsu CT, Wang CS, Kuo CF, Wang TH. A multicenter study on eradication of Helicobacter pylori infection in patients with duodenal ulcer by lansoprazole-antibiotics combined therapy. J Microbiol Immunol Infect 1999 32 : 1 8.
20. Sambrook J, Russell DW. Molecular Cloning: a Laboratory Manual, 3rd edn. Cold Spring Harbor, NY : Cold Spring Harbor Laboratory, 2001 6.8 6.10.
21. Morais SMF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994 46 : 594 8.
22. Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994 269 : 15419 22.
23. Nakai H, Shimamura Y, Kanazawa T, Yasuda S, Kayano M. Determination of a new H+-K+ ATPase inhibitor (E3810) and its four metabolites in human plasma by high-performance liquid chromatography. J Chromatogr B 1994 660 : 211 20.
24. Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 1979 25 : 358 71.
25. Mosteller RD. Simplified calculation of body surface area. N Engl J Med 1987 317 : 1098.
26. Padol S, Yuan Y, Thabane M, Padol IT, Hunt RH. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a meta-analysis. Am J Gastroenterol 2006 101 : 1467 75.
27. Sagar M, Tybring G, Dahl ML, Bertilsson L, Seensalu R. Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism. Gastroenterology 2000 119 : 670 6.
28. Shirai N, Furuta T, Moriyama Y, Okochi H, Kobayashi K, Takashima M, Xiao F, Kosuge K, Nakagawa K, Hanai H, Chiba K, Ohashi K, Ishizaki T. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 2001 15 : 1929 37.
29. Ieiri I, Kishimoto Y, Okochi H, Momiyama K, Morita T, Kitano M, Morisawa T, Fukushima Y, Nakagawa K, Hasegawa J, Otsubo K, Ishizaki T. Comparison of the kinetic disposition of and serum gastrin change by lansoprazole versus rabeprazole during an 8-day dosing scheme in relation to CYP2C19 polymorphism. Eur J Clin Pharmacol 2001 57 : 485 92.
30. Sugimoto M, Furuta T, Shirai N, Kajimura M, Hishida A, Sakurai M, Ohashi K, Ishizaki T. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. Clin Pharmacol Ther 2004 76 : 290 301.
31. Sugimoto M, Furuta T, Shirai N, Nakamura A, Kajimura M, Hishida A, Ohashi K, Ishizaki T. Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypes. Clin Pharmacol Ther 2005 77 : 302 11.
32. Yasuda S, Horai Y, Tomono Y, Nakai H, Yamato C, Manabe K, Kobayashi K, Chiba K, Ishizaki T. Comparison of the kinetic disposition and metabolism of E3810, a new proton pump inhibitor, and omeprazole in relation to S-mephenytoin 4′-hydroxylation status. Clin Pharmacol Ther 1995 58 : 143 54.
33. Williams MP, Blanshard C, Millson C, Sercombe J, Pounder RE. A placebo-controlled study to assess the effects of 7-day dosing with 10, 20 and 40 mg rabeprazole on 24-h intragastric acidity and plasma gastrin in healthy male subjects. Aliment Pharmacol Ther 2000 14 : 691 9.
34. Gambaro C, Bilardi C, Dulbecco P, Iiritano E, Zentilin P, Mansi C, Usai P, Vigneri S, Savarino V. Comparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a preliminary study. Dig Liver Dis 2003 35 : 763 7.
35. Isomoto H, Furusu H, Morikawa T, Mizuta Y, Nishiyama T, Omagari K, Murase K, Inoue K, Murata I, Kohno S. 5-day vs. 7-day triple therapy with rabeprazole, clarithromycin and amoxicillin for Helicobacter pylori eradication. Aliment Pharmacol Ther 2000 14 : 1619 23.
36. Wong BC, Wong WM, Yee YK, Hung WK, Yip AWC, Szeto ML, Li KF, Lau P, Fung FMY, Tong TSM, Lai KC, Hu WHC, Yuen MF, Hui CK, Lam SK. Rabeprazole-based 3-day and 7-day triple therapy vs. omeprazole-based 7-day triple therapy for the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2001 15 : 1959 65.
37. Erah PO, Goddard AF, Barrett DA, Shaw PN, Spiller RC. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. J Antimicrob Chemother 1997 39 : 5 12.
38. Ohning GV, Barbuti RC, Kovacs TO, Sytnik B, Humphries TJ, Walsh JH. Rabeprazole produces rapid, potent, and long-acting inhibition of gastric acid secretion in subjects with Helicobacter pylori infection. Aliment Pharmacol Ther 2000 14 : 701 8.